SPOTLIGHT -
Assessing the Durability and Toxicity of CAR T-Cell Therapy in DLBCL
Elise Chong, MD, discusses the rationale for conducting a 4-year analysis of tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
